Low density lipoproteins transactivate EGF receptor: Role in mesangial cell proliferation

Life Sciences

Volumn 83, Issue 17-18, 2008, Pages 595-601

  Kamanna, Vaijinath S ^a,b   Bassa, Babu V ^a,b   Ganji, Shobha H ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherogenic lipoproteins; EGF receptor; Glomerular disease; Low density lipoproteins; MAP kinase; Mesangial cell proliferation; Oxidized low density lipoproteins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CELL STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; MESANGIUM CELL; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; LIPOPROTEINS, LDL; MAP KINASE SIGNALING SYSTEM; MESANGIAL CELLS; MICE; OXIDATIVE STRESS; PHOSPHORYLATION; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 53249117060     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.08.010     Document Type: Article

References (60)

1. Abboud H.E. Growth factors in glomerulonephritis. Kidney Interernational 43 (1993) 252-267
2. Appel G. Lipid abnormalities in renal disease. Kidney International 39 (1991) 169-183
3. Avram M.M. Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens. A role for lipoprotein glomerulopathy. American Journal of Medicine 87 (1989) 39N-41N
4. Avram M.M., Goldwasser P., Burrell D.E., Antignani A., Fein P.A., and Mittman N. The uremic dyslipidemia: across-sectional and longitudinal study. American Journal of Kidney Disease 20 (1992) 324-335
5. Bassa B.V., Roh D.D., Kirschenbaum M.A., and Kamanna V.S. Atherogenic lipoproteins stimulate mesangial cell p42 mitogen-activated protein kinase. Journal of American Society of Nephrology 9 (1998) 488-496
6. Bassa B.V., Roh D.D., Vaziri N.D., Kirschenbaum M.A., and Kamanna V.S. Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCγ-1 and tyrosine kinase-Ras pathways. American Journal of Physiology 277 (1999) F328-F337
7. Berliner J.A., Territo M.C., Sevanian A., Ramin S., Kim J.A., Bamshad B., Esterson M., and Fogelman A.M. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. Journal of Clinical Investigation 85 (1990) 1260-1266
8. Border W.A., and Ruoslahti E. Transforming growth factor-β in disease. Journal of Clinical Investigation 90 (1992) 1-7
9. Bremer E.G., Schlessinger J., and Hakomori S. Ganglioside-mediated modulation of cell growth. Effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. Journal of Biological Chemistry 261 (1986) 2434-2440
10. Cushing S.D., Berliner J.A., Valente A.J., Territo M.C., Navab M., Parhami F., Gerrity R., Schwartz C.J., and Fogelman A.M. Minimally modified low density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. Proceedings of the National Academy of Science USA 87 (1990) 5134-5138
11. Daub H., Weiss F.U., Wallasch C., and Ullrich A. Role of transactivation of the EGF receptor in signaling by G protein-coupled receptors. Nature 379 (1996) 557-560
12. Eng E., Floege J., Young B.A., Couser W.G., and Johnson R.G. Does extracellular matrix expansion in glomerular disease requires mesangial cell proliferation?. Kidney International 45 (1994) S45-S47
13. Fornasieri A., Perugini C., Seccia M., Napodano P., D'Amico G., and Bellomo G. Circulating antibodies recognizing oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis, and focal glomerulosclerosis. Journal of Nephrology 15 (2002) 349-357
14. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta analysis. Kidney International 59 (2001) 260-269
15. Grewal J.S., Luttrell L.M., and Raymond J.R. G protein-coupled receptors desensitize and down-regulate epidermal growth factor receptors in renal mesangial cells. Journal of Biological Chemistry 276 (2001) 27335-27344
16. Grone E.F., Abboud H.E., Hohne M., Walli A.K., Grone H.J., Stuker D., Robenek H., Wieland E., and Seidel D. Actions of lipoproteins in cultured human mesagial cells. American Journal Physiology 263 (1992) F686-F696
17. Hackel P.O., Zwick E., Prenzel N., and Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Current Opinion in Cell Biology 11 (1999) 184-189
18. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 34 (1955) 1345-1353
19. Holvoet P., Donck J., Landeloos M., Brouwers E., Luijtens K., Arnout J., Lesaffre E., Vanrenterghem Y., and Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thrombosis and Haemostasis 76 (1996) 663-669
20. Itabe H., Yamamoto H., Imanka T., Shimamura K., Uchiyama H., Kimura J., Sanaka T., Hata Y., and Takano T. Sensitive detection of oxidatively modified low density lipoprotein using monoclonal antibody. Journal of Lipid Research 37 (1996) 45-53
21. Kamanna V.S., Bassa B., and Kirschenbaum M.A. Atherogenic lipoproteins induce mesangial cell protein tyrosine phosphorylation and activation of growth factor receptors. Journal of American Society of Nephrology 7 (1996) 1679A
22. Kamanna V.S., Pai R., Roh D.D., and Kirschenbaum M.A. Oxidative modification of low density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation and proliferation. Laboratory Investigation 74 (1996) 1067-1079
23. Kamanna V.S., Bassa B.V., and Kirschenbaum M.A. Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Current Opinion Nephrology and Hypertension 6 (1997) 205-211
24. Kamanna V.S., Pai R., Ha H., Kirschenbaum M.A., and Roh D.D. Oxidized low density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney International 55 (1999) 2192-2202
25. Kasiske B.L., O'Donnell M.P., Cleary M.P., and Keane W.F. Treatment of hyperlipidemia reduces glomerular injury in obese zucker rats. Kidney International 33 (1988) 667-672
26. Kasiske B.L., O'Donnell M.P., Garvis W.T., and Keane W.F. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circulation Research 62 (1988) 367-374
27. Kasiske B.L., O'Donnell M.P., Schmitz P.G., Kim Y., and Keane W.F. Renal injury of diet-induced hypercholesterolemia in rats. Kidney International 37 (1990) 880-891
28. Keane W.F., Kasiske B.L., and O'Donnell M.P. Lipids and progressive glomerulosclerosis. American Journal of Nephrology 8 (1988) 261-271
29. Keane W.F., O'Donnell M.P., Kasiske B.L., and Kim Y. Oxidative modification of low density lipoproteins by mesangial cells. Journal of American Society of Nephrology 4 (1993) 187-194
30. Klahr S., Schreiner G., and Ischikawa I. The progression of renal disease. New England Journal of Medicine 318 (1988) 1657-1666
31. Lee H.S., and Kim Y.S. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney International 54 (1998) 848-856
32. Lee H.S., Lee J.S., Koh H.I., and Ko K.W. Intraglomerular lipid deposition in routine biopsies. Clinical Nephrology 36 (1991) 67-75
33. Mackay K., Striker L.J., and Elliot S. Glomerular epithelial, mesangial and endothelial cell lines from transgenic mice. Kidney International 33 (1988) 677-684
34. Maggi E., Bellazzi R., Falaschi F., Frattoni A., Perani G., Finardi G., Gazo A., Nai M., Romanini D., and Bellomo G. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis. Kidney International 45 (1994) 876-883
35. Maggi E., Bellazzi R., Gazo A., Scccia M., and Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney International 46 (1994) 869-876
36. Maschio G., Oldrizzi L., Rugio C., Debiase V., and Loschiavo C. Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure. Kidney International 39 (1991) S70-S72
37. Moghal N., and Sternberg P.W. Multiple positive and negative regulators of signaling by the EGF-receptor. Current Opinion Cell Biology 11 (1999) 190-196
38. Morey A.K., Pedram A., Razandi M., Prins B.A., Hu R.M., Biesiada E., and Levin E.R. Estrogen and progesterone inhibit vascular smooth muscle cell proliferation. Endocrinology 138 (1997) 3330-3339
39. Nortwood I.C., and Davis R.J. Activation of the epidermal growth factor receptor tyrosine protein kinase in the absence of receptor oligomerization. Journal of Biological Chemistry 263 (1988) 7450-7453
40. O'Donnell M.P., Kasiske B.L., Kim Y., Atluru D., and Keane W.F. Lovastatin inhibits proliferation of rat mesangial cells. Journal of Clinical Investigation 91 (1993) 83-87
41. Pai R., Kirschenbaum M.A., and Kamanna V.S. Low density lipoprotein stimulates the expression of macrophage colony-stimulating factor in murine glomerular mesangial cells. Kidney International 48 (1995) 1254-1262
42. Parhami F., Fang Z.T., Fogelman A.M., Andalibi A., Territo M.C., and Berliner J.A. Minimally modified low density lipoprotein-induced inflammatory reponses in endothelial cells are mediated by cyclic adenosine monophosphate. Journal of Clinical Investigation 92 (1993) 471-478
43. 2+ in A431 carcinoma cells. Journal of Biological Chemistry 273 (1998) 3121-3124
44. Roh D.D., Kamanna V.S., and Kirschenbaum M.A. Oxidative modification of low density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins. American Journal of Nephrology 18 (1998) 344-350
45. Roh D.D., Kamanna V.S., and Kirschenbaum M.A. Atherogenic lipoproteins enhance murine cortical epithelial cell fibronectin protein synthesis and gene expression. American Journal of Nephrology 18 (1998) 83-88
46. Rosen L.B., and Greenberg M.E. Stimulation of growth factor receptor signal transduction by activation of voltage-sensitive calcium channels. Proceedings of the National Academy of Science USA 93 (1996) 1113-1118
47. Rovin B.H., and Tan L.C. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney International 43 (1993) 218-225
48. Samuelsson O., Aurell M., Knight-Gibson C., Alaupovic P., and Attman P.O. Apolipoprotein B-containing lipoproteins and the progression of renal insufficiency. Nephron 63 (1993) 279-285
49. Samuelsson O., Attman P.O., Gibson C., Larsson R., Mulec H., Weiss L., and Alaupovic P. Complex apolipoprotein B-containing lipoprotein particles are associated with a high rate of progression of human progressive renal insufficiency. Journal of American Society of Nephrology 9 (1998) 1482-1488
50. Sato H., Suzuki S., Kobayashi H., Ogino S., Inomata A., and Arakawa M. Immunohistological localization of apolipoproteins in the glomeruli in renal disease. Specifically apo B and apo E. Clinical Nephrology 36 (1991) 127-133
51. Satriano J.A., Shuldiner M., Hora K., Xing Y., Shan Z., and Schlondorff D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein JE/MCP-1 and the monocyte colony stimulating factor, CSF-1, in response to tumor necrosis factor-α and immunoglobulin G. Journal of Clinical Investigation 92 (1993) 1564-1571
52. Shoji T., fukomoto M., Kimito E., shinohara K., and Nishizawa Y. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney International 62 (2002) 2230-2237
53. Sparrow C.P., Parthasarathy S., and Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. Journal of Lipid Research 29 (1988) 745-753
54. Striker L.J., Doi T., Elliot S., and Striker G.E. The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Seminar in Nephrology 9 (1989) 318-328
55. Tits L., De Graaf J., Hak-Lemmers H., Bredie S., Demacker P., Holvoet P., and Stalenhoef A. Increased levels of low density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Laboratory Investigation 83 (2003) 13-21
56. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Seminar in Nephrology 24 (2004) 469-473
57. Wheeler D.C., Persaud J.W., Fernando R., Sweny P., Varghese Z., and Moorhead J.F. Effects of low density lipoproteins on mesangial cell growth and viability in vitro. Nephrology Dialysis and Transplantation 5 (1990) 185-191
58. Wolf G., Sharma K., Chen Y., Ericksen M., and Ziyadeh F.N. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney International 42 (1992) 647-656
59. Yoon J.W., Pahl M.V., and Vaziri N.D. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney International 71 (2007) 167-172
60. Zwick E., Daub H., Aoki N., Yamaguchi A., Tinhofer I., Maly K., and Ullrich A. Critical role of calcium-dependent epidermal growth factor receptor transactivation in PC12 cell membrane depolarization and bradykinin signaling. Journal of Biological Chemistry 272 (1997) 24767-24770